Health and Beauty

Skin Care Chestnut Hill Ma

  • What's hot

    MZ Skin Care - Chestnut Hill, MA Gift Card ($175)
    Gift Card

    List Price: $175.00
    Price: $175.00

    • All gift card orders for this merchant will be fulfilled with a Spa & Wellness Gift Card by Spa Week.
    • Located at: 1160 Boylston Street, Second Floor Chestnut Hill, MA 02467

Where to Get a Breast Examination Near Dedham

Brigham and Women's Nursing home offers mammography screenings at the following locations: 75 Francis St., Boston, 877-DFCI-BWH; 1153 Core St., Boston, 877-DFCI-BWH; and 850 Boylston St., Chestnut Hill, 877-DFCI-BWH. Boston's Mammography Van, in

Where to Get a Breast Examination in Newton

Newton-Wellesley Facility offers screenings and mammograms at its Washington Street locatino and at two off-plat Ambulatory Care Centers at 307 West Central St., Natick and 111 Norfolk St., Walpole. To register a Beth Israel Deaconess Hospital

¿Qué tipos de tatuajes son más difíciles de quitar?

¿Qué tipos de tatuajes son más difíciles de quitar? La mayoría de los pacientes podrían quitarse sus tatuajes con cuatro sesiones o menos, indicó uno de los autores del estudio, Nazanin Saedi, investigadora de SkinCare Physicians, en Chestnut Hill, Massachusetts, donde se realizó el estudio. Saedi ahora

Troubled Valeant unloads Dendreon, skin care brands for $2.1B in turnaround cash

Valeant plans to unload its equity interest in cancer drugmaker Dendreon, which has had a troubled history of its own, as well as its skincare brands CeraVe, AcneFree and AMBI.

Valeant agreed to offload those skincare brands to cosmetics giant L'Oréal for $1.3 billion in cash. The three products have annualized revenues of $168 million, Valeant said in a release. The deal, said CEO Joseph Papa, demonstrates the “progress” Valeant is making “in reshaping our product portfolio and driving value for our shareholders.” The company will use the proceeds to repay debt.

In the second deal, Valeant will sell its equity interest in Dendreon to China’s Sanpower Group for $819.9 million in cash, it said in a separate statement. Dendreon makes Provenge, a personalized immunotherapy for prostate cancer that attracted a lot of hype when it was approved by the FDA in 2010 but never quite caught fire in the oncology community. Valeant will pay down debt with those proceeds as well.